Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided a summary of key findings from the European Society for Medical Oncology (ESMO) Congress 2026. Following the presentation of several late-breaking datasets over the weekend, Natera’s technology was included in 25 abstracts, including 9 oral presentations, along with two concurrent publications. Results from the phase III VOLGA trial in muscle-invasive bladder canc